Input Symbol
(pharmaceutics and related company):

Show Other Options

US Clinical Trail Options
Field(s): Type(s): Status(es): Phase(s):
Default Sorting:
US FDA Submission Options
Field(s): Class(s): Type(s):
US Drug Marketing Status Options
Field(s):
EU Drug Marketing Status Options
Field(s):
CA Drug Marketing Status Options
Field(s):
General Options
Historical Years: Display Records Number:
Plot Options & Overlay
Price Chart: Technical Indicators: Clinical Trails: FDA Submissions:
US Marketing: EU Marketing: CA Marketing:
Full Name:Ultragenyx Pharmaceutical Inc. Industry:pharmaceuticals CIK:1515673 Fiscal Year End:12-31 State/Country:CALIFORNIA

Check Quant Chart for other overlays (E.g. SEC filings, Insider tradings) to get more accurate projection of price movement

Show Plot Instructions       Expand All

Instructions

US clinical trial status

Size of symbol reflects the phase of clinical trial. E.g. Phase 3 trial has the largest size.
Shape definition
Up-triangle: study first submitted.
Square: study completion(actual/anticipated).
Circle: result first posted.
Color definition
Green: study is ongoing.
Blue: recruitment completed.
Red: study aborted/terminated/withdrawn.
Pink: study in abnormal state.

US FDA submission

Size of symbol reflects the type of submission. E.g. Type 1 drug has the largest size.
: Approved.
: Tentative Approval.

Drug marketing & current status

Circle bubble denotes new drug marketing. Size is determined by drug type and market(i.e. population) size. E.g. Type 1 drug marketed in US has the largest size. Drug marketed in CA has the smallest size due to small population size.
Color definition
Blue circle: drug marketed (EU,CA), FDA submission approved (US).
Cyan circle: drug approved (CA), tentative approval (US), received positive opinion (EU)
Red circle: drug marketed/approved on the corresponding day but was later withdrawn, discontinued, cancelled, or received negative opinion.

Drug marketing status change

Square bubble denotes marketing status change. Size is determined by drug type and market(i.e. population) size.
Color definition
Blue square: change from other status to marketed.
Cyan square: change from other status to tentative status.
Red square: change from other status to abnormal or withdrawn status.

US Clinical Trials

Clinical Trials Summary Statistics

Year Recruiting Enrolling By Invitation Active, Not Recruiting Completed Terminated Withdrawn
ALL 1
2024
2023
2022
Year Recruiting Enrolling By Invitation Active, Not Recruiting Completed Terminated Withdrawn
ALL 2 3 3
2024
2023
2022
Year Recruiting Enrolling By Invitation Active, Not Recruiting Completed Terminated Withdrawn
ALL 10 3 2
2024
2023
2022 1
Year Recruiting Enrolling By Invitation Active, Not Recruiting Completed Terminated Withdrawn
ALL 1 1
2024
2023
2022
Year Recruiting Enrolling By Invitation Active, Not Recruiting Completed Terminated Withdrawn
ALL 3 1 1 3 2
2024
2023 2
2022 1
Year Phase 1 Phase 1|Phase 2 Phase 2 Phase 2|Phase 3 Phase 3
ALL 1 3
2024
2023 2
2022 1
Year Phase 1 Phase 1|Phase 2 Phase 2 Phase 2|Phase 3 Phase 3
ALL 1
2024
2023
2022
Year Phase 1 Phase 1|Phase 2 Phase 2 Phase 2|Phase 3 Phase 3
ALL 2 1 1
2024
2023
2022
Year Phase 1 Phase 1|Phase 2 Phase 2 Phase 2|Phase 3 Phase 3
ALL 1 3 10 3
2024
2023
2022
Year Phase 1 Phase 1|Phase 2 Phase 2 Phase 2|Phase 3 Phase 3
ALL 3 3 2
2024
2023
2022 1
Year Phase 1 Phase 1|Phase 2 Phase 2 Phase 2|Phase 3 Phase 3
ALL 2
2024
2023
2022
Phase Recruiting Enrolling By Invitation Active, Not Recruiting Completed Terminated Withdrawn
Phase 1 1
Phase 1|Phase 2 2 3 3
Phase 2 10 3 2
Phase 2|Phase 3 1 1
Phase 3 3 1 1 3 2
Phase Recruiting Enrolling By Invitation Active, Not Recruiting Completed Terminated Withdrawn
Phase 1
Phase 1|Phase 2
Phase 2
Phase 2|Phase 3
Phase 3
Phase Recruiting Enrolling By Invitation Active, Not Recruiting Completed Terminated Withdrawn
Phase 1
Phase 1|Phase 2
Phase 2
Phase 2|Phase 3
Phase 3 2
Phase Recruiting Enrolling By Invitation Active, Not Recruiting Completed Terminated Withdrawn
Phase 1
Phase 1|Phase 2
Phase 2 1
Phase 2|Phase 3
Phase 3 1

Note: "Year" represents clinical trail start year determined by study first submit date.
Three grouping strategies present the same statistical data from different angles, choose any one you are comfortable with.
at least one study with latest update posted within 7 days.  at least one study with latest update posted within 30 days.  at least one study with latest update posted within 90 days. 

Clinical Trials Records

Sponsor Overall Status Phase Brief Title Disease Condition Intervention Name Study First Submit Date Last Update Post Date Results First Post Date Completion Date Completion Date Type Enrollment Count
Ultragenyx Pharmaceutical Inc Recruiting Phase 3 A Study to Determine the Effect of Triheptanoin Compared With Even-chain, MCT on MCEs in Pediatric Patients With LC-FAOD Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Triheptanoin|MCT Oil 2023-06-27 2024-04-25 2026-09-01 Anticipated 60
Ultragenyx Pharmaceutical Inc Recruiting Phase 3 Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Osteogenesis Imperfecta Bisphosphonate|Setrusumab 2023-03-03 2024-04-09 2026-06-01 Anticipated 66
Ultragenyx Pharmaceutical Inc Recruiting Phase 3 Clinical Study of DTX301 AAV- Mediated Gene Transfer for Ornithine Transcarbamylase(OTC) Deficiency OTC Deficiency DTX301|Placebo|Oral Corticosteroids|Placebo for oral corticosteroids|Sodium Acetate 2022-04-18 2024-04-03 2028-12-01 Anticipated 50

Note: Use 'Search' box on top right cornor to narrow down search results. E.g. type in "phase 3" (case insensitive, with double quote) to show Phase 3 trials.
latest update posted within 7 days.  latest update posted within 30 days.  latest update posted within 90 days. 

US FDA Submissions

US FDA Submission Summary Statistics*

Year TYPE 1
ALL 2
2024
2023
2022

Note: "Year" determined by submission status date.
* Original submissions only. Supplementary records not counted.
at least one submission within 7 days.  at least one submission within 30 days.  at least one submission within 90 days. 

US FDA Submission Records

No FDA submission record found matching current filtering criteria

Note: Use 'Search' box on top right cornor to narrow down search results. E.g. type in "NDA" (case insensitive) to show records with "NDA" (New Drug Applications) tag.
submission status date within 7 days.  submission status date within 30 days.  submission status date within 90 days. 

US Drug Marketing Status

No marketed drug found matching current filtering criteria

Note: This table contains human and animal drugs regulated by US FDA, and biological products regulated by CBER (Center for Biologics Evaluation and Research).
Use 'Search' box on top right cornor to narrow down search results. E.g. type in "discontinued" (case insensitive) to show discontinued drug products.
For human non-bioproduct, marketing date was set to submission approval date.
Possible marketing statuses: Marketed, Prescription, Over-the-counter, Discontinued, None (Tentative Approval).
any of (marketing/submission/status change) within 7 days.  any of (marketing/submission/status change) within 30 days.  any of (marketing/submission/status change) within 90 days. 

EU Drug Marketing Status

No marketed drug found matching current filtering criteria

Note: This table contains human and animal drugs regulated by EMA (European Medicines Agency), and summary of opinion published by EMA based on the CHMP's or CVMP's positive or negative recommendation.
Use 'Search' box on top right cornor to narrow down search results. E.g. type in "withdrawn" (case insensitive) to show drugs withdrawn.
Possible marketing statuses: Authorised, Refused, Withdrawn, Summary of Opinion.
Summary of Opinion: published by European Medicines Agency (EMA) based on the CHMP's or CVMP's positive or negative recommendation. Further marketing authorization is partially based on this opinion.
any of (authorization/withdrawn/opinion/status change) date within 7 days.  any of (authorization/withdrawn/opinion/status change) date within 30 days.  any of (authorization/withdrawn/opinion/status change) date within 90 days. 

CA Drug Marketing Status
Category Sponsor Authorization Date Current Marketing Status Status Date Drug Name Active Ingredient
Human Ultragenyx Pharmaceutical Inc 2023-09-22 Marketed 2023-11-21 Evkeeza Evinacumab (150 Mg)

Note: This table contains human, animal drugs, radiopharmaceutical and disinfectant regulated by CFIA(Canadian Food Inspection Agency) and Health Canada.
Use 'Search' box on top right cornor to narrow down search results. E.g. type in "marketed" (case insensitive) to show drugs marketed.
Possible marketing statuses: Marketed, Approved, Dormant, Cancelled Pre Market, Cancelled Post Market, Cancelled (Safety Issue), Cancelled (Unreturned Annual).
any of (authorization/status change) date within 7 days.  any of (authorization/status change) date within 30 days.  any of (authorization/status change) date within 90 days.